We studied the effects of a
5-lipoxygenase inhibitor, L-651,192, on the pulmonary dysfunction caused by
endotoxemia in chronically instrumented unanesthetized sheep. The efficacy and selectivity of
L-651,392 were tested by measuring in vivo production of
leukotriene B4 (
LTB4) and
cyclooxygenase products of
arachidonic acid after
endotoxemia before and after pretreatment with
L-651,392 and ex vivo from granulocytes and whole blood stimulated with
calcium ionophore from sheep before and 24 h after pretreatment with
L-651,392. A novel assay for
LTB4 by high-performance liquid chromatography/gas chromatography/mass spectrometry techniques was developed as a measure of
5-lipoxygenase metabolism of
arachidonic acid.
L-651,392 proved to be an effective in vivo
5-lipoxygenase inhibitor in sheep.
L-651,392 blocked the increase in
LTB4 observed in lung lymph after
endotoxemia in vivo in sheep as well as inhibited by 80% the ex vivo production of
LTB4 by granulocytes removed from sheep treated 24 h earlier with
L-651,392. Although
L-651,392 blocked the increase in
cyclooxygenase products of
arachidonic acid observed in lung lymph after
endotoxemia in vivo in sheep, the
drug probably did not function directly as a
cyclooxygenase inhibitor.
L-651,392 did not attenuate the ex vivo production of
thromboxane B2 by whole blood from sheep treated 24 h earlier with the
drug.
L-651,392 attenuated the alterations in pulmonary hemodynamics, lung mechanics, oxygenation, and lung fluid and solute exchange observed after
endotoxemia in sheep. We speculate that
5-lipoxygenase products are a major stimulus for
cyclooxygenase metabolism of
arachidonic acid after
endotoxemia in sheep.